The SSRIs have become the most heavily prescribed antidepressant drugs in North America and Europe. However, they have been dogged by controversy about withdrawal effects/drug dependence, heightened suicidal thinking and behaviour, and their use in children and adolescents who are depressed. This paper brings the reader up to date with developments, including opinion and guidance from the MHRA and NICE.
